FGFR2 and invasive ductal breast carcinoma: While FGFR2’s role in endocrine resistance is established, its potential involvement in shaping immune infiltration—particularly in the transition from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC)—remains underexplored.